Literature DB >> 23291380

Prevalence of pneumococcal disease, serotype distribution, and antimicrobial susceptibility in Mexican children younger than 5 years of age.

Aurora Bautista-Márquez1, Vesta Richardson, Oscar Ortiz-Orozco, Maria Edilia Luna-Cruz, M Noemí Carnalla-Barajas, Gabriela Echaniz-Avilés, Miriam Bobadilla-del Valle, Lucila Martínez-Medina, Ana María Montalvo-Vázquez, Norma de la Re-Montaño, Ivette Anchondo-Martínez, Juan Carlos Tinoco-Favila, Gerardo Martínez-Aguilar, Israel Yberri-Zárate, José Antonio Girón-Hernández, José Sifuentes-Osornio, M Lourdes Guerrero, Guillermo M Ruiz-Palacios.   

Abstract

BACKGROUND AND AIMS: Streptococcus pneumoniae constitutes one of the main causes of sepsis, bacteremia and meningitis (pneumococcal invasive disease - PID), and pneumonia in infants and small children. Antipneumococcal vaccination in Mexico is expected to be a useful strategy to reduce morbimortality due to this cause. We undertook this study to determine the prevalence of PID and pneumonia and the PCV vaccination status of affected children as well as serotype distribution and antimicrobial susceptibility of pneumococcal strains responsible for PID in infants and small children in Mexico.
METHODS: From March 2010-June 2011, a prospective multicenter study was carried out in four states in Mexico to determine the prevalence of bacteremia, meningitis, septic arthritis and pneumonia due to S. pneumoniae and other microorganisms in children from 28 days-59 months of age. Isolated pneumococcal strains were serotyped and their antimicrobial resistance determined.
RESULTS: During the study period, 545 children were diagnosed with bacteremia, meningitis, septic arthritis or pneumonia; 46.7% of these clinical entities occurred among children <12 months of age. Community-acquired pneumonia was the most prevalent disease. It was possible to identify a causal microorganism in 55 cases, from which 80% were S. pneumoniae. Fifteen percent of patients with PID died. The most prevalent pneumococcal serotypes were 19A, 35B, 19F and 6A. 10.2% of nonmeningeal strains were resistant to meropenem and 82% were resistant to TMP/SMX.
CONCLUSIONS: This study shows that pneumococcus was the most common bacteria isolated in the studied population, although epidemiological and laboratory-based surveillance still needs improvement.
Copyright © 2013 IMSS. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23291380     DOI: 10.1016/j.arcmed.2012.12.005

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  4 in total

1.  Early trends in invasive pneumococcal disease in children following the introduction of 13-valent pneumococcal conjugate vaccine: results from eight years of active surveillance in a Mexican hospital.

Authors:  Enrigue Chacon-Cruz; R M Rivas-Landeros; M L Volker-Soberanes
Journal:  Ther Adv Vaccines       Date:  2014-11

2.  Changing trends in serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae causing invasive diseases in Central Thailand, 2009-2012.

Authors:  Wanatpreeya Phongsamart; Somporn Srifeungfung; Tanittha Chatsuwan; Pongpun Nunthapisud; Vipa Treerauthaweeraphong; Pimpha Rungnobhakhun; Sirintip Sricharoenchai; Kulkanya Chokephaibulkit
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Mathematical modeling of postcoinfection with influenza A virus and Streptococcus pneumoniae, with implications for pneumonia and COPD-risk assessment.

Authors:  Yi-Hsien Cheng; Shu-Han You; Yi-Jun Lin; Szu-Chieh Chen; Wei-Yu Chen; Wei-Chun Chou; Nan-Hung Hsieh; Chung-Min Liao
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-07-05

4.  The global burden of hospitalisation due to pneumonia caused by Staphylococcus aureus in the under-5 years children: A systematic review and meta-analysis.

Authors:  Durga Kulkarni; Xin Wang; Emma Sharland; Daniel Stansfield; Harry Campbell; Harish Nair
Journal:  EClinicalMedicine       Date:  2022-01-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.